Pharma, healthcare sector deals hit US$ 3.5 billion in September quarter: Report
- IBEF
- October 29, 2025
India’s pharmaceutical and healthcare sector witnessed robust deal momentum in Q3 CY25, recording 72 transactions worth Rs. 30,902 crore (US$ 3.5 billion), according to Grant Thornton Bharat’s Dealtracker. This included three Initial public offerings (IPOs) valued at Rs. 3,779 crore (US$ 428 million) and one Qualified Institutional Placement (QIP) worth Rs. 777 crore (US$ 88 million). Excluding public market activity, private deals accounted for Rs. 26,487 crore (US$ 3 billion) across 68 transactions, signalling renewed investor confidence. The surge was driven by seven high-value deals worth Rs. 22,955 crore (US$ 2.6 billion), underscoring the sector’s strong fundamentals and investor appetite for scale, innovation, and consolidation across pharmaceutical, biotech, and hospital segments.
The standout deal was Torrent Pharma’s Rs. 12,361 crore (US$ 1.4 billion) acquisition of a 46% stake in JB Chemicals & Pharmaceuticals, bolstering its presence in chronic care and high-growth therapeutic areas. Mergers and acquisitions (M&A) activity rose sharply to 36 deals worth Rs. 22,073 crore (US$ 2.5 billion), a 57% increase in volume from the previous quarter. Private equity (PE) deals reached 32, valued at Rs. 3,752 crore (US$ 425 million), with investors showing preference for early- and mid-stage opportunities in health tech, wellness, and pharma services. The rebound highlights growing optimism around India’s life sciences ecosystem, driven by consolidation, capability enhancement, and innovation-led growth.
Disclaimer: This information has been collected through secondary research and IBEF is not responsible for any errors in the same.
Partners
